Saturday, September 25, 2021 – 07:49 WIB
–
Sinovac’s Covid-19 vaccine. Photo: Ricardo/JPNN.com
jpnn.com, KUALA LUMPUR – Efficacy vaksin Sinovac had been in the spotlight after a number of health care workers in Indonesia and Thailand were reported to have contracted COVID-19 even though they had received vaccinations of this type.
However, recent research has found that Sinovac’s COVID-19 vaccine is highly effective at protecting humans from becoming seriously ill.
However, the results of the research conducted by the Malaysian government also found that the vaccines made by Pfizer/BioNTech and AstraZeneca show a higher level of protection.
The research was carried out by the Institute for Clinical Research together with a national task force for handling COVID-19.
The results of the research found that 0.011 percent of the approximately 7.2 million people who were injected with the Sinovac vaccine required treatment in a hospital intensive care unit (ICU) due to COVID-19 infection, several health officials told reporters, Thursday (23/9).
Meanwhile, the number of recipients of Pfizer/BioNTech and AstraZeneca doses who were treated in the ICU due to COVID-19 infection was 0.002 percent and 0.001 percent, respectively.
Kalaiarasu Peariasamy, director of the Institute for Clinical Research, said that vaccination — with a vaccine made by any pharmaceutical company — had reduced people’s risk of being admitted to the ICU by 83 percent.
It said vaccination also lowered the risk of death by 88 percent.
–
The results of Malaysian research provide good news for residents who have been injected with the Sinovac vaccine, listen carefully.
– .